JAK1 and rheumatoid arthritis: Upadacitinib, taken at 15 mg once daily, is a JAK1 inhibitor approved to treat rheumatoid arthritis, psoriatic arthritis, atopic dermatitis and moderate-to-severe active ulcerative colitis (289).